Besides PD-L1 modulation on tumor cell lines, it has been recently reported that the HDAC6i inhibitor ACY-241, in combination with oxaliplatin, modulates PD-L1 level on TAMs in a mouse model of non-small cell lung cancer (NSCLC) (20). The gene discussed is CD274; the disease is neoplasm.